Review for best practice in clinical rheumatology juvenile systemic sclerosis – Updates and practice points

2021 ◽  
pp. 101688
Author(s):  
Ivan Foeldvari ◽  
Kathryn S. Torok
Keyword(s):  
Systemic Sclerosis ◽  
Best Practice ◽  
Clinical Rheumatology ◽  
Juvenile Systemic Sclerosis

scholarly journals AB0237 INFECTIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH RITUXIMAB AND ANTI-TNF INHIBITOR

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1144.2-1144
Author(s):  
N. Zehraoui ◽  
R. Benaziez.Boutaleb ◽  
H. Hafirassou ◽  
F. Mechid ◽  
N. Bahaz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Best Practice ◽  
Biological Therapy ◽  
Patient Characteristics ◽  
Inadequate Response ◽  
Tnf Inhibitor ◽  
Clinical Rheumatology ◽  
Number Of Patients ◽  
Serious Infections ◽  
Comparative Risk

Background:Biological therapies have significantly improved the management of rheumatoid arthritis (RA). These molecules are very effective, but are known for their specific risks, especially infectious. It depends on several factors including the type of molecule used.Objectives:The objective of our study is to compare the rate of infection in RA patients treated with rituximab and anti-TNFα.Methods:Prospective, observational, monocentric study. Were included RA patients (ACR / EULAR 2010 criteria) treated with rituximab and anti-TNFα (adalimumab, infliximab and Etanercept) after inadequate response to DMARDs.Demographic characteristics, comorbidities, association with methotrexate and corticosteroids were collected and compared for each group.The number, type and severity of the infections in both cases were noted.SPSS (Statistical Package for Social Science) was used for data analysis.Results:40 RA patients treated with rituximab and 31 patients who received anti-TNFα were included.Patient characteristics and Comparison of rate of infection in RA patients between the two groups are summarized in Table 1Table 1.ParametersRituximabAnti-TNFαpNumber of patients4031Average age (years)56,2846,060,01Sexratio0,140,110,7Average duration of evolution (years)15,8313,740,3Patients under corticosteroid (%)97,587,10,08Average corticosteroid dose6,415,480,3patients under methotrexate (%)37,545,20,5Diabetes (%)2016,10,7Patients with infection (%)32,551,60,1Number of infections18240,4Number of serious infections500,04Conclusion:The rate of infections in patients with RA treated with rituximab or anti-TNF was similar. However, the infections observed were more serious in patients with RA treated with rituximabReferences:[1]Fabiola Atzeni MD PhD and al. Infections and Biological Therapy in Patients with Rheumatic Diseases. IMAJ . VOL 18. march-APRIL 2016.[2]Huifeng Yun and al. Comparative Risk of Hospitalized Infection Associated with Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. ARTHRITIS & RHEUMATOLOGY. Vol. 68, No. 1, January 2016, pp 56–66.[3]Manjari Lahiri and al. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Practice & Research Clinical Rheumatology (2015) 1-16.Disclosure of Interests:None declared

scholarly journals Juvenile systemic sclerosis: review of 15 patients

2014 ◽  
Vol 12 (S1) ◽  
Author(s):  
Sandra I Sousa ◽  
Susana Fernandes ◽  
Paula Estanqueiro ◽  
Carla Zilhão ◽  
Catarina Resende ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
Juvenile Systemic Sclerosis

T lymphocyte abnormalities in juvenile systemic sclerosis patients

2013 ◽  
Vol 149 (1) ◽  
pp. 146-155 ◽  
Author(s):  
Andreas Reiff ◽  
Kenneth I. Weinberg ◽  
Timothy Triche ◽  
Bernadette Masinsin ◽  
Kris M. Mahadeo ◽  
...  
Keyword(s):  
Systemic Sclerosis ◽  
T Lymphocyte ◽  
Juvenile Systemic Sclerosis

scholarly journals Successful Treatment with Bosentan for Pulmonary Hypertension and Reduced Peripheral Circulation in Juvenile Systemic Sclerosis

2011 ◽  
Vol 32 (7) ◽  
pp. 1040-1042 ◽  
Author(s):  
Masaki Shimizu ◽  
Yoko Hashida ◽  
Kazuyuki Ueno ◽  
Tadafumi Yokoyama ◽  
Yuko Nakayama ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Systemic Sclerosis ◽  
Successful Treatment ◽  
Peripheral Circulation ◽  
Juvenile Systemic Sclerosis

Juvenile Systemic Sclerosis: A Follow-up Study of Eight Patients

2005 ◽  
Vol 1051 (1) ◽  
pp. 229-234 ◽  
Author(s):  
SZILVIA SZAMOSI ◽  
LÁSZLÓ MARÓDI ◽  
LÁSZLÓ CZIRJÁK ◽  
ZOLTÁN ELLENES ◽  
GABRIELLA SZÜCS
Keyword(s):  
Systemic Sclerosis ◽  
Follow Up Study ◽  
Juvenile Systemic Sclerosis

scholarly journals An interim report of the Scleroderma Clinical Trials Consortium working groups

2018 ◽  
Vol 4 (1) ◽  
pp. 17-27 ◽  
Author(s):  
Murray Baron ◽  
Bashar Kahaleh ◽  
Elana J Bernstein ◽  
Lorinda Chung ◽  
Philip J Clements ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Systemic Sclerosis ◽  
Observational Studies ◽  
Scleroderma Renal Crisis ◽  
The World ◽  
Juvenile Systemic Sclerosis ◽  
Working Groups ◽  
Disease Damage ◽  
Vascular Component ◽  
Lord Kelvin

The Scleroderma Clinical Trials Consortium represents many of the clinical researchers in the world who are interested in improving the efficiency of clinical trials in systemic sclerosis. The Scleroderma Clinical Trials Consortium has established 11 working groups to develop and validate better ways of measuring and recording multiple aspects of this heterogeneous disease. These include groups working on arthritis, disease damage, disease activity, cardiac disease, juvenile systemic sclerosis, the gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung disease, and skin measurement. Members of the Scleroderma Clinical Trials Consortium may join any one or more of these groups. Some of the working groups have only recently started their work, some are nearing completion of their mandated tasks, and others are in the midst of their projects. All these projects, which are described in this article, will help improve clinical trials and observational studies by improving or developing better, more sensitive ways of measuring various aspects of the disease. As Lord Kelvin stated, “To measure is to know. If you cannot measure it you cannot improve it.” The Scleroderma Clinical Trials Consortium is dedicated to improving the lives of patients with systemic sclerosis and it is our hope that the contributions of the working groups will be one important step in this process.

scholarly journals Juvenile Systemic Sclerosis- A Case Report

2018 ◽  
Vol 29 (2) ◽  
pp. 70-72
Author(s):  
ASMM Rahman ◽  
MB Uddin
Keyword(s):  
Case Report ◽  
Systemic Sclerosis ◽  
Rare Disease ◽  
Clinical Presentation ◽  
Organ Involvement ◽  
Published Data ◽  
Multisystem Disorder ◽  
Adult Disease ◽  
Adult Form ◽  
Juvenile Systemic Sclerosis

Juvenile systemic sclerosis (JSS) is a multisystem disorder as well as rare disease of childhood, and the amount of published data is limited. It appears that its clinical presentation differs from adult disease and the limited form affects only very few children. The organ involvement pattern differs also from the adult form. Prognosis seems to be better with a 5-yr survival of 95% of the JSS patients. Though the incidence is very rare but we describe a 10-yr-old boy who presented with typical features of JSS.TAJ 2016; 29(2): 70-72

Sign in / Sign up

Export Citation Format

Share Document